thecryptobasic.com
18 m
$XRP consolidated for roughly two years before launching into a historic rally in 2017 and 2018.
Vandell Aljarrah, co-founder of Black Swan Capitalist, called attention to this history in a recent post on X. He used it to urge investors not to lose patience during prolonged market stagnation.
Aljarrah stressed that $XRP’s historical price action is a reminder of how long consolidation can precede a major market expansion.
“Losing patience during market stagnation is a novice mistake,” he wrote. He recalled how $XRP consolidated for approximately two years before executing a 62,000% macro expansion phase in 2017 and 2018.
The accompanying $XRP/USD weekly chart illustrates the extended trading range that preceded the rally. $XRP spent roughly 742 days consolidating around the $0.004–$0.011 range before breaking out in 2017 and eventually reaching its cycle peak in January 2018.
The chart’s measurement highlights the scale of the subsequent advance, showing a 630X price gain.
$XRP 1-Week Chart Showing 630% Price Surge in 2017/2018
Meanwhile, Aljarrah’s post prompted a discussion about just how much $XRP gained during its historic run.
One commenter argued that the rally was closer to 64,000%, measuring the move from approximately $0.006 to $XRP’s all-time high of $3.84. Aljarrah responded that the percentage depends on the starting point and exchange used to determine the price.
He argued that measuring from $XRP’s 2014 cycle lows to its January 2018 peak produces a much larger gain of approximately 119,000%.
Depends where you measure it from exactly, and what exchange you're looking at. If you measure from the cycle lows of 2014 to the cycle high in Jan 2018 it was actually a 119,000% move up.
Not everyone agreed that $XRP’s previous rally offers a useful template for the current market.
One commenter argued that today’s cryptocurrency market differs considerably from the 2017–2018 cycle. He cited the influence of market makers and alleged corruption as reasons not to expect a repeat performance.
Another questioned $XRP’s long-term value, arguing that its previous rise from fractions of a cent to several dollars had not translated into comparable subsequent price appreciation.
These concerns highlight doubts about whether $XRP’s past price patterns can predict its future, given how much the crypto market has changed.
$XRP is currently trading at $1.34, up 2.6% over the past 24 hours, according to the CoinMarketCap data provided in the report.
At this price, $XRP remains approximately 65% below its previous peak of $3.84. A 62,000% increase from its current price of $1.34 would push $XRP to approximately $832. Many analysts consider such a price target unrealistic in the short term, although they may view it as a possibility over several decades.
Ultimately, Aljarrah’s argument rests on the idea that patience is important during prolonged periods of limited price movement, as recovery phases may eventually follow. For context, $XRP recorded a price surge of nearly 700% during the 2024–2025 market cycle.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight
Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.
Eli Lilly (LLY.US) "lowers its stance" and joins forces with former rival Hims (HIMS.US) to compete for the self-pay weight loss drug market
Eli Lilly is collaborating with Hims & Hers Health, leveraging the telehealth company’s large customer base to expand access to its blockbuster weight loss drugs and boost sales of medications, including its new oral weight loss drug Foundayo.
"Predicting Your Prediction" Intensifies Tech Stock Sell-off! After $2.3 Trillion Market Value Evaporates, Has the "Hot Money" Mechanical Selling Still Not Subsided?
The Nasdaq 100 Index fell by 6.4%, wiping out $2.3 trillion in market capitalization. The core reason behind this decline is concerns that a comprehensive victory by the Democratic Party could lead to stricter regulations on AI development. Systematic funds, which typically follow the stock market's trend and respond to price fluctuations and momentum signals, were thus forced to reduce their investments, accelerating the downturn. The selling pressure from systematic strategies may not be over yet; it is expected that in the coming days, portfolios targeting volatility will sell at least $50 billion worth of stocks.
The midterm election tears open the "abyss" of AI trading, facing a moment of reckoning for trillion-dollar capital expenditure narratives
For months, investors have been worried about a series of risks behind the AI (artificial intelligence) capital expenditure "money tree." This week, the market finally pressed the panic selling button.
